Home News News

Akava Therapeutics, Inc. shares recent data suggesting that AKV9 acts on a common mechanism involved in both Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS)

May 9, 2025

Read More

News

‘Remarkable’ ALS Drug May Also Work on Alzheimer’s

April 9, 2025

Read More

Home News News

Akava Therapeutics, Inc. congratulates SAB Chair Dr. Hande Ozdinler, Founder Dr. Richard B. Silverman, and Dr. William Klein on their recent grant of $7.3 million from the National Institute on Aging to investigate AKV9 in neurodegenerative diseases

December 19, 2024

Read More

Home News News

National Institute on Aging invests an additional $7.3 million into NU-9

December 17, 2024

Read More

Home News

Akava Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for the Treatment of Amyotrophic Lateral Sclerosis

August 22, 2023

Read More

Home News News

Richard B. Silverman elected to the National Academy of Sciences

May 16, 2023

Read More

Home News

Drug Hunter Interview

January 26, 2023

Drug Hunter Flash Talk with Prof. Hande Ozdinler, Ph.D. and Prof. Richard B. Silverman, Ph.D.

Read More

A Long Swim

January 26, 2023

A Long Swim co-founder and executive director Doug McConnell sits down with Dr. Hande Ozdinler, A Long Swim Director of…

Read More

News

Akava receives Orphan Drug Designation status for AKV9

July 6, 2022

Akava Therapeutics, Inc. announces that on July 6, 2022, orphan drug designation (ODD) status was received for AKV9 for the…

Read More

News

ALS drug breakthrough shows promise in animal studies

July 1, 2022

Read More